Navigation Links
AutoGenomics Receives FDA Clearance for its INFINITI® CYP2C19 Assay
Date:10/26/2010

VISTA, Calif., Oct. 26 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay.  The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.  

"We are very excited to receive FDA clearance for our 2C19 test" said Fareed Kureshy, President and CEO of AutoGenomics. "The necessity of this genetic test has been implicated in literature now for several years.  The FDA has now provided clinicians with a tool in determining medical strategies for therapeutics that are metabolized by the CYP 450 2C19 gene test specifically * 2, *3, *17. This is an important milestone in the era of personalized medicine. Several of our customers are awaiting such clearance to implement testing in their practice." He further said, "we continue to expand our portfolio of FDA cleared products." "The INFINITI® CYP 450 2C19 test is unique in evaluating *17 which can help clinicians identify ultra metabolizers" said Robert Cole, MD., Chief Medical Officer at AutoGenomics

The INFINITI® System features a broad menu of 42 applications, with 5 FDA cleared products and 16 CE marked products.

About AutoGenomics

AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. www.autogenomics.com


'/>"/>
SOURCE AutoGenomics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference
2. AutoGenomics New RVP Assay Addresses Current Challenge to Detect Flu A - Swine H1N1
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
5. UCLA engineering receives $6M to construct new state-of-the-art building
6. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
7. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
8. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
9. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
10. Xiaoguang Meng receives honorary master of engineering from Stevens
11. AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Kurzlehrgang mit Fokus auf ... Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... ... Yoav Peretz , Scientific Director bei ImmuneCarta, einen ... zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen ...
(Date:2/18/2017)... ... 2017 , ... A leader in science-based, age-fighting skincare products, ... is proud to introduce its Age-Defying Night Cream, NeriumAD™ Formula, Age-Defying Day Cream, ... Hong Kong. The luxury skincare products contain innovative ingredients that fight the signs ...
(Date:2/17/2017)... , February 17, 2017 ... "Biomarkers Market by Product (Consumables, Service), Type (Safety, ... (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - ... market is projected to reach USD 53.34 Billion ... growing at a CAGR of 13.8% during the ...
(Date:2/17/2017)... Feb. 17, 2017  If only one in ... a mutation-conferring resistance to chemotherapy, thousands of cancer ... has focused on finding these mutations in ever-smaller ... circulating tumor DNA in blood — to guide ... Unfortunately, however, detecting these genetic anomalies ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
(Date:1/24/2017)...  It sounds simple and harmless—an electronic sensor ... signs and alerts parents on their smart phones ... drops. But pediatric experts argue that such devices ... evidence of medical benefits, especially to healthy babies. ... parents of healthy babies, promising peace of mind ...
Breaking Biology News(10 mins):